anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine compound for treating headache. The traditional Chinese medicine compound comprises rhizoma corydalis, radix angelicae, millettia specisoa champ., chuanxiong rhizomas, fructus viticis, rhizoma ligustici, medicinal cyathula roots, kudzuvine roots, radix scutellariae, herba asari and liquorice roots. According to the traditional Chinese medicine compound for treating headache, rhizoma corydalis, chuanxiong rhizomas and radix angelicae serve as the sovereign drugs and achieves the effects of eliminating qi stagnation, removing stasis and dredging brain collaterals to relieve pain; millettia specisoa champ. is capable of dredging collaterals and relieving urgent symptoms, kudzuvine roots are capable of dredging channels and resolving tetany, fructus viticis is capable of soothing collaterals and dispelling wind, and the materials assist the sovereign drugs in promoting qi to activate blood, dispersing blood stasis, dredging channels, soothing collaterals, relieving urgent symptoms and dredging qi and blood; meanwhile, rhizoma ligustici is combined for dispelling wind disturbance of brain apertures, medicinal cyathula roots are combined for ensuring proper downward flow of blood, radix scutellariae is combined for clearing away superficial heat, herba asari guides all other materials to enter brain channels and dispels wind to relieve pain, the materials serve as adjuvant drugs and achieve the effects of reinforcing and activating collaterals and relieving pain, and liquorice roots coordinate actions of all the drugs and serves as a conductant drug. All materials in the whole prescription work together to achieve the effects of promoting qi to activate blood and activating meridians to stop pain. The traditional Chinese medicine compound for treating headache is minor in side effect, sufficient in drug amount, quick in effectiveness, lasting in treatment effect after the compound becomes effective and good in cure effect, and drug loading capacity is obviously higher than that of preparations on the market.
The study design will include patients with open surgical repair of the thoracoabdominal aorta who underwent thoracophrenolumbotomy with retroperitoneal exposure of the aorta. It is assumed the lymphoblock to reduce the incidence of postoperative lympho-/chylorrhea. Patients will be divided based on randomization into groups that will receive a lymphoblock or a placebo. It is planned to recruit 138 patients, 69 patients in each group. The drug will be used right before wound closure. The solution will be applied to the surface of the wound with further exposure and draining. Blood test and drainage discharge parameters (from the left pleural cavity and retroperitoneum) will be examined in postoperative period. The thoracic and abdominal CT and ultrasound will be performed to exclude presence of effusion and/or lymphocele.
The Stem Cell Delivery Device comprises an Introducer, a Catheter, and Pressure Metered Injector Syringe. The device and method aim to deliver stem cells abundantly enough at the damaged site to allow recovery and restore function. The Method uses activated Stem Cells. It entails injecting via the Syringe Injector the epidural space with raw adipose tissue extract to circle the spinal cord about a level above and below the injured cord site till blockade of the subarachnoid space of the injured spinal cord site is achieved and radiographically verified. Then washed activated stem cells are injected via the Syringe into the blocked subarachnoid space to bridge between the upper and lower normal spinal tract, allowing the stem cells to grow new spinal tracts to connect and bridge over the damaged site. IV infusion of bone marrow stem cells is added to maximize the chance of recovery.
Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved over the past few decades, relapsed ALL remains a leading cause of mortality in children with cancer. Risk has been defined by the International (I) Berlin, Frankfurt, Münster (BFM) Study Group (SG) based on duration of first remission, immunophenotype of malignant clone, and site of relapse. Patients classified as high risk (HR) by these criteria have poor response rates to standard induction therapy, high rates of subsequent relapse and require an allogeneic hematopoetic stem cell transplantation (allo-HSCT) for consolidation of 2nd remission. Over the last decade members of the I-BFM-SG have investigated the use of different combinations of conventional cytotoxic agents. Even with allo-HSCT, none of these approaches have improved outcome above 40%. Therefore, for HR patients there is a need to investigate the curative potential of new agents combined with systemic therapy. The proteasome inhibitor bortezomib has shown synergistic activity with acceptable toxicity when combined with corticosteroids, anthracyclines and alkylating agents in adult patients with cancer as well as with dexamethasone, doxorubicin, vincristine and polyethylene glycol (PEG) asparaginase in children with refractory or relapsed ALL. In the I-BFM-SG International Study for Treatment of High Risk Childhood Relapsed ALL (IntReALL) HR 2010 study, the potential of Bortezomib combined with a modified ALL relapse protocol 3 (R3) backbone as induction regimen for HR patients to improve complete 2nd remission (CR2) rates will be investigated in a randomized phase II design. Induction is followed by conventional intensive consolidation. After termination of the trial patients may be subjected to an investigational window, before all of them receive allo-HSCT.
A water-soluble pharmaceutical composition containing an edaravone/cyclodextrin inclusion compound is disclosed. The composition comprises edaravone and cyclodextrin in a mass ratio of 1:9-1:60, wherein the cyclodextrin is hydroxypropyl-beta-cyclodextrin, or sulfobutylether-beta-cyclodextrin, or hydroxypropyl-sulfobutyl-beta-cyclodextrin, or a cyclodextrin mixture of the hydroxypropyl-beta-cyclodextrin, the sulfobutyl ether-beta-cyclodextrin and the hydroxypropyl-sulfobutyl-beta-cyclodextrin in any proportion. The composition is cyclodextrin/edaravone in an inclusion state. Under a condition that pH is 6.9, the inclusion stability constant Ka of the cyclodextrin/edaravone is 1331-2822 M<-1>. The composition increases the solubility of the edaravone, can be clear and stable for a long period of time, and is stable in content. The composition facilitates increase of brain tissue medicine concentrations, changes medicine distribution and enhances curative effects. The composition is low in hemolysis and non-irritating, thus facilitating improvement of pharmacy safety. The composition is easy to carry, convenient to store, simple in clinical using method, easy in operation and high in practicability. A preparing method is simple, simple and convenient in operation, low in cost and free of environment pollution.
After consent is obtained, eligible patients (moderate or complex ACHD, stages B, C, or D) will complete the baseline study measures assessment and be randomized to receive PRISM or usual care (anticipated n=86, 43 per group). Patients in the intervention group will participate in the six PRISM sessions over 3 months. At 3 months following enrollment, patients in both groups will again complete study measures. We will define feasibility as a) the proportion of eligible patients who enroll and b) the proportion of patients who complete the intervention among those randomized to intervention. We will define preliminary efficacy as the change in mean resilience from baseline to 3 months after randomization between those randomized to intervention and usual care. Exploratory analyses will examine PRISM's impact on patient-centered outcomes of quality of life, symptoms of anxiety and depression, and perceived competence for health care.
Studies on the carcinogenicity of talc have been performed using non-standard designs which prevent firm conclusions on its carcinogenicity. With single intraperitoneal administration to mice at 20 mg and observation for at least 6 months or 4 weekly doses administered intraperitoneally at 25 mg/dose to rats with observation for at least 84 weeks, tumor incidence was not increased. In these studies the talc and its asbestos content were not characterized.

Genotoxicity was tested in cultures of rat pleural mesothelial cells (RPMC) as unscheduled DNA synthesis (UDS) and sister chromatid exchanges (SCEs). None of the talc samples (which were asbestos-free) induced enhancement of UDS or SCEs in treated cultures. No information is available on impairment of fertility in animals by talc.
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least 202 evaluable participants. Data will be collected in an observer-blind manner. Study product recipients and study staff responsible for the evaluation of any study endpoint will be unaware of whether Bexsero or placebo were administered. Participants who consent to screening will have baseline clinical information collected at Visit 0, Screening (Day -14 \[Window -45 to -7\]). This information will consist of medical history, concomitant medications, physical exam, sexual history, and clinical and laboratory findings. Participants will undergo a physical exam and have blood drawn to establish baseline laboratory values for safety assessment. Urine or a vaginal swab, and a rectal swab will be collected for Nucleic Acid Amplification Test (NAAT) for gonorrhea and chlamydia. A pharyngeal swab will be collected for NAAT testing of gonorrhea. At the enrollment visit, Visit 1, participants who test negative for gonorrhea and who otherwise qualify will be enrolled and randomized in a 1:1 ratio to receive the initial intramuscular (IM) dose of study product. A phone call, Visit 2, will be held approximately 30 days after the initial study product dose was received and will be conducted with all participants to assess for safety events in the interim. At Visit 3, the participant will receive the second dose of study product. Visit 4 will be held 1 month after second dose. At 3-month intervals, through the final study follow-up visit, participants will have clinic study visits, Visit 5 thru Visit 8. The duration of the study for participants who are enrolled and randomized will be approximately 16 months. For those not enrolled, participation could end at their Visit 0, Screening; post Visit 0, Screening based on NAAT test results; or Visit 1, Enrollment. Study participation is expected to be completed in approximately 36 months. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection. The secondary objectives are to estimate efficacy of Bexsero in prevention of overall gonococcal infection and by anatomical site (urogenital, anorectal or pharyngeal) and to assess safety of Bexsero.
FIELD: medicine, ophthalmology. SUBSTANCE: method deals with treating dystrophic diseases of retina and an optic nerve. Firstly, one should resect conjunctiva and Tenon's membrane to form a pouch in Tenon's space, then a purse-string suture is applied and a peptide bioregulator is introduced into Tenon's space at 1000-10000 Da molecular weight isolated out of retina or bovine brain cortex, correspondingly, then a purse-string suture is tightened up. The method provides prolonged supply of preparation from Tenon's space into area of pathological process. EFFECT: higher efficiency of therapy. 2 cl, 6 dwg, 3 ex
Subjects will be using investigational or control tampons during their menstrual period but these tampons are not intended to prevent, treat or diagnose an infection or other disease condition. This study will be a randomized, single-blinded, multi-center study of women using Tampons with GML, Tampons without GML or the Tampons Normally Used for one menstrual period. Subjects will undergo Baseline microflora evaluations taken from the vaginal walls 5-10 days following their menstrual period (Baseline evaluation). Subjects will be randomly assigned to use one of the three study products during their next menstrual period. Microflora will be re-evaluated in samples taken from the tampons and from the vaginal walls during use of the study tampons, and from vaginal walls soon after the end of the menstrual period. Evaluations of microflora will be done by quantitative cultures of tampons and vaginal swabs, and also by Nugent scoring of the vaginal swabs. Staphylococcal α-hemolysin and TSST-1 will be analyzed in extracts of the study tampons from subjects found to be colonized with S. aureus. Vaginal pH will be measured, using electronic meters, at each clinic visit. All samples (tampons and vaginal swabs) will be analyzed at a central microbiology laboratory. Extracts of tampons found to contain S. aureus will be forwarded to another central laboratory for the toxin assays. Personnel in the central laboratories will be blinded to the group assignment (study product) for each subject until completion of the study.
Use of zinc acexamate for the preparation of a pharmaceutical composition for the treatment of inflammatory bowel disease in humans. A subject of the invention is a new use of zinc acexamate, for the preparation of a pharmaceutical composition for the treatment in humans of Inflammatory Bowel Disease. Preferably the pharmaceutical composition is for the treatment in humans of Ulcerative Colitis and/or Crohn's Disease. Zinc acexamate can be the only active ingredient or it can be in combination with other active ingredients. The pharmaceutical composition is intended for oral and/or rectal administration and is preferably administered in a unit dose form comprising between 20 and 500 mg of zinc acexamate. (Machine-translation by Google Translate, not legally binding)
The recommended start time for image acquisition is 60 minutes after PYLARIFY injection. Starting image acquisition more than 90 minutes after injection may adversely impact imaging performance. Patients should void immediately prior to image acquisition. Position the patient supine with arms above the head. Image acquisition should start from mid-thigh and proceed to the skull vertex. Scan duration is 12 minutes to 40 minutes depending on the number of bed positions (typically 6 to 8) and acquisition time per bed position (typically 2 minutes to 5 minutes).
PURPOSE: Enhanced recovery after surgery (ERAS) protocols lead to reduced post-operative stay and improved outcomes after most types of abdominal surgery. Little is known about the optimal post-operative protocol after robotic ventral hernia repair (RVHR), including the potential limits of outpatient surgery. We report the results of an ERAS protocol after RVHR aiming to identify factors associated with overnight stay in hospital, as well as patient-reported pain levels in the immediate post-operative period.
METHODS: This was a prospective cohort study of consecutive patients undergoing RVHR. Patients were included in a prospective database, registering patient characteristics, operative details, pain and fatigue during the first 3 post-operative days and pre- and 30-day post-operative hernia-related quality of life, using the EuraHS questionnaire.
RESULTS: A total of 109 patients were included, of which 66 (61%) underwent incisional hernia repair. The most performed procedure was TARUP (robotic transabdominal retromuscular umbilical prosthetic hernia repair) (60.6%) followed by bilateral roboTAR (robotic transversus abdominis release) (19.3%). The mean horizontal fascial defect was 4.8 cm, and the mean duration of surgery was 141 min. In total, 78 (71.6%) patients were discharged on the day of surgery, and factors associated with overnight stay were increasing fascial defect area, longer duration of surgery, and transverse abdominis release. There was no association between post-operative pain and overnight hospital stay. The mean EuraHS score decreased significantly from 38.4 to 6.4 (P < 0.001).
CONCLUSION: An ERAS protocol after RVHR was associated with a high rate of outpatient procedures with low patient-reported pain levels.
This is a multi-center, randomized, double-blind, placebo-controlled study to determine the efficacy and tolerability of REN-1654 in subjects with sciatica. After screening and baseline clinical assessments, subjects will be randomly assigned to receive REN 1654 100 mg or matching placebo, once daily for 3 weeks. Leg pain, back pain and other efficacy measures will be assessed at 1 and 3 weeks after initiation of treatment. A subset of patients will undergo analysis of blood levels of REN-1654 during the course of the study (pharmacokinetics). Subjects will discontinue treatment after 3 weeks and return after a further 3 weeks off therapy for a final clinical assessment 6 weeks after initiation of treatment. If a subject does not return for follow-up, an effort will be made by telephone to document their clinical status and whether other interventions have been made.
The present invention provides a precious metal alloy consisting essentially of palladium and up to 25% tin, up to 2% iron, up to 1% aluminium, and up to 11/2% boron. In its preferred form the tin content is approximately 15%, the iron content is approximately 0.83%, the aluminum content is approximately 0.5%, and the boron content is approximately 0.17%. The alloy has a melting point of approximately 2650° F. It is especially adapted for low-fusing porcelain application, and well suited for dental use. It is an economy precious metal alloy as it contains no gold and no platinum. Between 1% and 5% of ruthenium may be added as a hardening element. 3% of ruthenium has been found to be ideal.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes analogs of Δ12,13-isotaxol of the formula (I) Δ where values   and X 1  R 1 -R 8  are given in p. 1 of the invention claim. Compounds of the formula (I) are useful for treatment of patients with cancer diseases involving human ovary cancer, breast cancer, malignant melanoma, lung cancer, rectum bowel cancer, head and neck cancer and leukosis where taxol shows the high effectiveness. Invention describes also intermediate compounds, a method of synthesis of intermediate compounds and a pharmaceutical composition based on compounds of the formula (I). EFFECT: improved method of synthesis, enhanced an antitumor effectiveness of compounds. 25 cl, 17 dwg, 3 tbl, 13 ex
A soap comprising: 0.5 to 90 wt% sodium, potassium, and/or ammonium salts of fatty acids having 6-30 carbon atoms; and 1 to 50 wt% one or more biosurfactants. Preferably the biosurfactant is a glycolipid, a lipopeptide. Preferably the biosurfactant is a rhamnolipid, a sophorolipid, a mannosylerythritol, a surfactin, a fatty acyl glutamate, a fatty acyl glycinate or a combination thereof. Preferably the soap comprises sodium salts of tallow fatty acids, coconut fatty acids, olive oil fatty acids, palm oil fatty acids, lard fatty acids, palm kernel oil fatty acids or a combination thereof. The soap may comprise 0.1 to 10 wt% of a non-ionic surfactant, preferably an alkyl polyglucoside, a fatty acyl glucamide, or a combination thereof. The soap may comprise one or more additional components selected from fillers, free fatty acids, fragrances or perfumes, antioxidants, complexing agents, caring substances and humectants.
A medical system comprises a medical instrument system and an assembly removably coupled to the medical instrument system. The assembly is configured to operate the medical instrument system by moving it within an anatomic passageway. The medical system also comprises a sensor system coupled to the instrument system and configured to generate information including spatial data and shape data about the instrument system. The medical system also comprises a control system communicatively coupled to the instrument system, the assembly, and the sensor system. The control system receives, from the sensor system, a first set of the spatial data including position information for a distal end of the medical instrument system during a plurality of time periods. The control system also receives the shape data from the sensor system and filters the first set of the spatial data.
This is a randomized cross-over study of zinc absorption in young children living in the Western Highlands of Guatemala. Absorption of zinc will be measured from maize tortillas and maize tortillas fortified with 20% amaranth as the major food staple which provides at least 70% energy and at least 90% zinc and phytate of the diet. Participants will be randomized as to which type of tortilla they receive on the first and second day. Fractional absorption of zinc (FAZ) from all meals in one day for one type of tortilla and one day for the other will be measured by extrinsic labeling with stable isotopes of zinc. FAZ will be measured by a dual isotope tracer ratio (DITR) technique based on ratio of urine enrichment of orally versus intravenously administered zinc stable isotopes. Measurement of total zinc in duplicate diets on test days allow for determination of quantities of this micronutrient absorbed.
INTRODUCTION: The Fundamental Critical Care Support Course (FCCS) is a standardized multidisciplinary program designed to educate participants on the basics of identification and management of patients with critical illness. Our objective was to evaluate the effect of FCCS participation on confidence in the assessment and management of critically ill patients and attitudes towards multidisciplinary education and interprofessional care in a multidisciplinary group of participants.
METHODS: Participants enrolled in the FCCS course from May 2018 to November 2019 were solicited to participate in a series of surveys evaluating their course experience and confidence in critical care. Attitudes towards multidisciplinary education and interprofessional care were evaluated using the Student Perceptions of Interprofessional Clinical Education-Revised Instrument version 2 (SPICE-R2) tool. A prospective pre- and post-design with a self-report survey including retrospective pre-training assessment and a 3-month follow-up was conducted. Statistical analysis was performed using descriptive statics and non-parametric methods.
RESULTS: 321 (97.9%) of the course participants enrolled in the study and completed the confidence survey and SPICE-R2 tool pre-course. Nurses (113, 35.4%) and physicians (110, 34.4%) made up the largest groups of participants, although physician assistants and paramedics were also well represented. Confidence in recognition and management of critical illness significantly improved across all studied domains after course completion, with the mean total confidence score improving from 32.96 pre-course to 41.10 post-course, P < 0.001. Attitudes towards multidisciplinary education and interprofessional care also improved (mean score 41.37 pre-course vs 42.71 post-course, P < 0.001), although pre-course numbers were higher than expected which limited the significance to only certain domains.
DISCUSSION: In a multidisciplinary group, completion of FCCS training led to increased confidence in all aspects of critical illness measured. A modest increase in attitudes regarding multidisciplinary education and interprofessional care was also demonstrated. Further study is needed to assess whether this increased confidence translates to improvements in patient care and outcomes.